FULC
Income statement / Annual
Last year (2024), Fulcrum Therapeutics, Inc.'s total revenue was $80.00 M,
an increase of 2,752.05% from the previous year.
In 2024, Fulcrum Therapeutics, Inc.'s net income was -$9.73 M.
See Fulcrum Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$80.00 M |
$2.81 M |
$6.34 M |
$19.16 M |
$8.82 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$63.39 M
|
$0.00
|
$76.78 M
|
$69.70 M
|
$59.04 M
|
$2.05 M
|
$1.35 M
|
$715.00 K
|
| Gross Profit |
$16.61 M
|
$2.81 M
|
-$70.44 M
|
-$50.54 M
|
-$50.22 M
|
-$2.05 M
|
-$1.35 M
|
-$715.00 K
|
| Gross Profit Ratio |
0.21
|
1
|
-11.11
|
-2.64
|
-5.69
|
0
|
0
|
0
|
| Research and Development Expenses |
$63.39 M
|
$71.80 M
|
$76.78 M
|
$69.70 M
|
$59.04 M
|
$43.43 M
|
$25.18 M
|
$18.49 M
|
| General & Administrative Expenses |
$34.97 M
|
$41.67 M
|
$41.69 M
|
$30.52 M
|
$21.39 M
|
$0.00
|
$8.31 M
|
$4.50 M
|
| Selling & Marketing Expenses |
$1.48 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$36.45 M
|
$41.67 M
|
$41.69 M
|
$30.52 M
|
$21.39 M
|
$13.15 M
|
$8.31 M
|
$4.50 M
|
| Other Expenses |
-$61.32 M
|
$0.00
|
-$76.36 M
|
-$69.70 M
|
-$59.04 M
|
$0.00
|
$392.00 K
|
$28.00 K
|
| Operating Expenses |
$38.51 M
|
$113.47 M
|
$42.12 M
|
$30.52 M
|
$21.39 M
|
$56.57 M
|
$33.50 M
|
$22.99 M
|
| Cost And Expenses |
$101.90 M
|
$113.47 M
|
$118.90 M
|
$100.22 M
|
$80.43 M
|
$58.63 M
|
$33.50 M
|
$22.99 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$207.00 K
|
$792.00 K
|
$1.51 M
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.59 M
|
$2.17 M
|
$2.41 M
|
$2.52 M
|
$2.38 M
|
$2.05 M
|
$1.35 M
|
$715.00 K
|
| EBITDA |
-$18.24 M |
-$108.49 M |
-$109.72 M |
-$78.54 M |
-$69.23 M |
-$80.62 M |
-$32.15 M |
-$22.28 M |
| EBITDA Ratio |
-0.23
|
-38.68
|
-17.3
|
-4.1
|
-7.85
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.27
|
-39.45
|
-17.75
|
-4.23
|
-8.12
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$12.17 M
|
$13.33 M
|
$2.69 M
|
$207.00 K
|
$792.00 K
|
-$24.05 M
|
$910.00 K
|
$29.00 K
|
| Income Before Tax |
-$9.73 M
|
-$97.34 M
|
-$109.87 M
|
-$80.85 M
|
-$70.82 M
|
-$82.68 M
|
-$32.59 M
|
-$22.96 M
|
| Income Before Tax Ratio |
-0.12
|
-34.7
|
-17.32
|
-4.22
|
-8.03
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.00 K
|
| Net Income |
-$9.73 M
|
-$97.34 M
|
-$109.87 M
|
-$80.85 M
|
-$70.82 M
|
-$82.68 M
|
-$32.59 M
|
-$22.96 M
|
| Net Income Ratio |
-0.12
|
-34.7
|
-17.32
|
-4.22
|
-8.03
|
0
|
0
|
0
|
| EPS |
-0.16 |
-1.59 |
-2.35 |
-2.22 |
-2.7 |
-3.49 |
-1.92 |
-1.36 |
| EPS Diluted |
-0.16 |
-1.59 |
-2.35 |
-2.22 |
-2.7 |
-3.49 |
-1.92 |
-1.36 |
| Weighted Average Shares Out |
$61.98 M
|
$61.31 M
|
$44.99 M
|
$35.36 M
|
$25.35 M
|
$22.66 M
|
$16.94 M
|
$16.94 M
|
| Weighted Average Shares Out Diluted |
$61.98 M
|
$61.31 M
|
$44.99 M
|
$35.36 M
|
$25.35 M
|
$22.66 M
|
$16.94 M
|
$16.94 M
|
| Link |
|
|
|
|
|
|
|
|
